Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.80 | N/A | +34.91% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.80 | N/A | +34.91% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding market conditions. They highlighted their commitment to navigating through challenges while focusing on future growth.
Management acknowledged ongoing challenges in the market.
They emphasized a focus on long-term strategies despite current setbacks.
Ionis Pharmaceuticals reported a larger-than-expected loss per share, which was a positive surprise compared to consensus expectations. However, the lack of revenue data and no guidance updates contributed to a negative stock reaction, with shares falling 2.3%. Investors may be concerned about the company's future performance given the current market challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Keurig Dr Pepper Inc.